Early lung cancer signs could be spotted in urine

A groundbreaking urine test has been developed by scientists that could potentially detect early signs of lung cancer. In the UK, most cases of lung cancer are diagnosed at later stages, making treatment more challenging. However, researchers are hopeful that with early detection, patients could receive treatment sooner, increasing their chances of overcoming the disease.

The innovative test looks for specific “zombie” cell proteins that may indicate the presence of early-stage lung cancer. Successful trials on mice have paved the way for human trials to begin soon. Scientists from the University of Cambridge and the Early Cancer Institute have studied proteins excreted by senescent cells, known as “zombie cells”, which can contribute to tissue damage and cancer development.

The researchers have designed an injectable sensor that reacts with these proteins, releasing a detectable compound into urine to indicate their presence. This method aims to identify changes in lung tissue before cancer fully emerges, potentially allowing for early intervention months or even years before symptoms become apparent.

Funded by Cancer Research UK, the team behind the test aims to create a cost-effective, easy-to-use detection method as an alternative to expensive scans. They plan to move beyond pre-clinical stages and assess the test’s effectiveness in human subjects, with aspirations to adapt the technology for other types of cancer as well.

Dr Iain Foulkes, from Cancer Research UK, emphasised the importance of early detection in improving cancer outcomes and lauded the project led by Professor Fruk. With lung cancer remaining a significant health concern in the UK, this new urine test could potentially revolutionise early cancer detection and save more lives.

In summary, the development of a urine test for early lung cancer detection brings hope for improving survival rates and treatment outcomes. The innovative approach of targeting specific proteins in urine could pave the way for cost-effective and accessible early cancer detection methods, benefiting high-risk individuals and those at risk of cancer recurrence. Further research and clinical trials will be crucial in validating the effectiveness of this promising technology across various types of cancer.